Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

The test, which Santa Maria, California-based Hardy distributes in the US under a license from NG Biotech, is designed to detect CTX-M enzymes.

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.